The structure-interaction model of polymyxin lipopeptides with human oligopeptide transporter 2

This study elucidates the structure-interaction relationship between polymyxin lipopeptides and the human oligopeptide transporter hPepT2 through integrated computational and experimental approaches, identifying critical binding residues and demonstrating that specific analogues with reduced hPepT2 interaction retain antibacterial efficacy while significantly lowering nephrotoxicity.

The Gist

🦠 The Problem: The "Last Resort" Drug with a Deadly Side Effect

Imagine you have a very dangerous infection caused by "superbugs" (bacteria that have learned to ignore almost all our medicines). The only weapon left in our medical arsenal is a class of drugs called Polymyxins. Think of Polymyxins as the "nuclear option" of antibiotics—they are incredibly effective at killing these superbugs.

However, there's a catch. While these drugs are great at killing bacteria, they are also very toxic to human kidneys. In fact, up to 60% of patients who take them suffer kidney damage. It's like using a sledgehammer to kill a fly; it works, but you might break the table (your kidney) in the process.

Why does this happen?
Our kidneys are designed to filter blood and keep good things (like nutrients) while throwing away waste. Unfortunately, our kidneys have a specific "pickup truck" (a transporter protein called hPepT2) that is supposed to grab small peptides (protein fragments) from the blood and recycle them.

The problem is that Polymyxins look a little bit like these protein fragments. So, the kidney's pickup truck mistakenly grabs the Polymyxin drugs, pulls them inside the kidney cells, and holds onto them. Once trapped inside, the drugs build up, causing the cells to die and the kidney to fail.

🔍 The Mission: How to Trick the Kidney

The scientists in this paper wanted to solve a puzzle: How exactly does the kidney's pickup truck (hPepT2) grab the Polymyxin drug?

If they could figure out the "lock and key" mechanism, they could redesign the drug (the key) so that it still kills the bacteria but no longer fits into the kidney's pickup truck. This would stop the drug from getting trapped in the kidney, saving the organ while still curing the infection.

🧪 The Detective Work: Computer Simulations and Mutant Trucks

1. The Virtual Simulation (The Movie)
First, the researchers used powerful computers to build a 3D movie of the kidney transporter (hPepT2) and the Polymyxin drug interacting.

• They found that the drug doesn't just bump into the truck; it slides into a specific side door (a "lateral opening").
• They discovered that the drug has several "sticky hands" (positively charged parts) that grab onto specific "magnets" (negatively charged spots) on the truck.
• The Analogy: Imagine the drug is a Velcro ball. The kidney truck has specific Velcro patches. The study mapped out exactly which patches the ball sticks to.

2. The Lab Experiment (The Mutant Trucks)
To prove their computer movie was real, they went into the lab. They took the gene for the kidney transporter and created "mutant" versions where they removed or changed those specific "magnet" spots.

• Result: When they removed a specific magnet (called D215), the truck completely stopped grabbing the Polymyxin drug. This confirmed that D215 is the most critical spot for the drug to latch on.

🧬 The Solution: Designing a "Stealth" Drug

Now that they knew exactly how the kidney grabs the drug, they decided to build a new version of the drug that the kidney would ignore.

They created five new versions of the Polymyxin drug. In the original drug, the "sticky hands" (specific parts of the molecule) were perfect for grabbing the kidney truck. In the new versions, they swapped those sticky hands for "smooth hands" (Alanine) that the kidney truck couldn't grab.

The Results:

• The Kidney Test: They tested these new drugs in mice. The original drug caused kidney damage. One of the new versions, called FADDI-795, was a total game-changer. The mice took the drug, and their kidneys remained perfectly healthy. The kidney truck simply couldn't grab it!
• The Bacteria Test: Would this "stealth" drug still kill the superbugs? Yes! FADDI-795 killed the bacteria just as well as the original drug.

🏆 The Big Takeaway

This study is a massive success story in "rational drug design." Instead of guessing and hoping for a better drug, the scientists:

1. Mapped the interaction between the drug and the body.
2. Identified the exact point of failure (the kidney grabbing the drug).
3. Redesigned the drug to break that specific connection.

In simple terms: They figured out that the kidney was "hugging" the drug too tightly. They redesigned the drug so the kidney lets go, but the bacteria still gets crushed. This opens the door to creating a new generation of antibiotics that are powerful against superbugs but safe for our kidneys.

The Lead Character: The star of this show is FADDI-795, a new drug candidate that kills bad bacteria without hurting the patient's kidneys. It's a promising step toward a future where we don't have to choose between curing an infection and damaging our organs.

Technical Summary

1. Problem Statement

• Global Health Crisis: Multidrug-resistant (MDR) Gram-negative bacteria (e.g., Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae) pose a critical threat, leaving polymyxins (e.g., Polymyxin B) as the last-line therapy.
• Clinical Limitation: The clinical utility of polymyxins is severely restricted by nephrotoxicity, affecting up to 60% of patients.
• Mechanistic Gap: Previous studies established that the human oligopeptide transporter 2 (hPepT2) mediates the extensive reabsorption of polymyxins in renal proximal tubular cells, leading to intracellular accumulation and toxicity. However, the specific structure-interaction relationship (SIR) between polymyxins and hPepT2 remained unknown, hindering the rational design of safer analogues.

2. Methodology

The study employed an integrated computational, chemical, and cell biology approach:

• Computational Modeling:
  • Structure Prediction: Used AlphaFold2 and homology modeling (based on rat PepT2 Cryo-EM structures) to generate an outward-facing conformation of hPepT2, as the experimental structure was unavailable.
  • Molecular Dynamics (MD): Conducted both Coarse-Grained (CG) and All-Atom MD simulations to visualize the binding pathway of Polymyxin B to hPepT2 and identify key interaction residues.
• Functional Mutagenesis:
  • Generated alanine-scanning mutants of predicted negatively charged residues (Asp/Glu) on hPepT2 to test their role in polymyxin binding.
  • Assessed transporter function using uptake assays with the standard substrate [³H]Gly-Sar and a fluorescent polymyxin probe (MIPS-9541).
  • Analyzed kinetic parameters ($K_m$, $V_{max}$) and protein expression levels (total cell and cell surface) via Western blotting and biotinylation.
• Chemical Biology & Drug Design:
  • Synthesized five polymyxin B analogues with alanine substitutions at specific diaminobutyric acid (Dab) residues (Dab1, Dab3, Dab5, Dab8, Dab9) predicted to interact with hPepT2.
• Pharmacological Evaluation:
  • Tested Minimum Inhibitory Concentrations (MICs) against various MDR strains.
  • Evaluated nephrotoxicity in a mouse model using histological scoring.

3. Key Contributions

• First SIR Model: Established the first computationally predicted and experimentally validated structure-interaction relationship model between polymyxins and hPepT2.
• Mechanistic Insight: Identified that polymyxins enter hPepT2 via a lateral opening gate rather than a traditional central pore, driven by electrostatic interactions between the cationic Dab residues of polymyxin and specific anionic residues on hPepT2.
• Rational Drug Design: Successfully translated the SIR model into the design of novel lipopeptide analogues that disrupt transporter binding while retaining antibacterial efficacy.

4. Key Results

• Structural Modeling:
  • MD simulations revealed a transport pathway where Polymyxin B binds to the lateral opening site of hPepT2 (involving TM1-TM6 and TM7-TM12 bundles).
  • Key interacting residues on hPepT2 were predicted to be E79, D208, E214, D215, D317, D342, E555, and E622.
• Mutagenesis Validation:
  • Critical Residue: The D215 residue was confirmed as critical for polymyxin binding; the D215A mutant showed a doubled $K_m$ (reduced affinity) but an increased $V_{max}$, suggesting compensatory turnover.
  • Expression vs. Binding: Mutants E214A, E555A, and E622A showed reduced uptake primarily due to decreased protein expression (lower $V_{max}$), whereas D342A showed reduced binding affinity ($K_m$) with unchanged $V_{max}$.
  • Substrate Specificity: Some mutants (e.g., D317A, E555A) showed differential effects on Gly-Sar vs. Polymyxin uptake, indicating distinct but overlapping binding pockets.
• Analogues Performance:
  • Reduced Uptake: Analogues FADDI-170, FADDI-175, FADDI-793, and FADDI-795 (substituting Dab1, Dab3, Dab5, or Dab9) showed significantly reduced hPepT2-mediated cellular uptake compared to wild-type Polymyxin B.
  • Lead Compound (FADDI-795):
    • Antibacterial Activity: Retained potent activity against MDR strains (comparable to Polymyxin B), with some strains showing even better susceptibility.
    • Safety: In mouse models, FADDI-795 showed no observable nephrotoxicity, whereas Polymyxin B and other analogues caused kidney damage.

5. Significance

• Proof-of-Concept: This study demonstrates that disrupting the specific interaction between antibiotics and renal transporters (hPepT2) is a viable strategy to mitigate nephrotoxicity without compromising antibacterial potency.
• Drug Discovery Pipeline: The identified SIR model provides a blueprint for the rational design of next-generation lipopeptide antibiotics that avoid renal reabsorption.
• Clinical Impact: The lead compound, FADDI-795, represents a promising candidate for treating MDR Gram-negative infections with a significantly improved safety profile, potentially overcoming the major dose-limiting toxicity of current polymyxin therapies.
• Methodological Advance: The integration of AlphaFold2, long-timescale MD simulations, and chemical biology offers a robust framework for studying transporter-drug interactions where experimental structures are lacking.